|
US7608693B2
(en)
*
|
2006-10-02 |
2009-10-27 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human IL-4 receptor
|
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
|
US20130064834A1
(en)
|
2008-12-15 |
2013-03-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to pcsk9
|
|
BR112013008366B1
(pt)
|
2010-10-06 |
2022-02-08 |
Regeneron Pharmaceuticals, Inc |
Formulações farmacêuticas líquidas estáveis contendo anticorpos anti-receptor de interleucina-4 humana alfa, e recipiente contendo as referidas formulações
|
|
PL3395836T3
(pl)
|
2011-01-28 |
2021-12-13 |
Sanofi Biotechnology |
Ludzkie przeciwciała przeciwko pcsk9 do zastosowania w sposobach leczenia konkretnych grup osobników
|
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
|
ES2992345T3
(es)
|
2011-09-16 |
2024-12-11 |
Regeneron Pharma |
Métodos para reducir los niveles de lipoproteína(a) mediante la administración de un inhibidor de la proproteína convertasa subtilisina kexina-9 (PCSK9)
|
|
PL3574897T3
(pl)
|
2011-11-18 |
2022-05-09 |
Regeneron Pharmaceuticals, Inc. |
Postać użytkowa o przedłużonym uwalnianiu zawierająca mikrocząstki białka polimerowego do stosowania w ciele szklistym oka w leczeniu naczyniowych zaburzeń oczu
|
|
AU2013212587B2
(en)
|
2012-01-23 |
2017-07-20 |
Regeneron Pharmaceuticals, Inc. |
Stabilized formulations containing anti-Ang2 antibodies
|
|
JO3820B1
(ar)
|
2012-05-03 |
2021-01-31 |
Regeneron Pharma |
أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
|
|
US20140004131A1
(en)
*
|
2012-05-04 |
2014-01-02 |
Novartis Ag |
Antibody formulation
|
|
AR092325A1
(es)
*
|
2012-05-31 |
2015-04-15 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
|
|
JP6306588B2
(ja)
|
2012-08-21 |
2018-04-04 |
サノフィ・バイオテクノロジー |
Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
|
|
US8883979B2
(en)
*
|
2012-08-31 |
2014-11-11 |
Bayer Healthcare Llc |
Anti-prolactin receptor antibody formulations
|
|
US9592297B2
(en)
*
|
2012-08-31 |
2017-03-14 |
Bayer Healthcare Llc |
Antibody and protein formulations
|
|
PL2892927T3
(pl)
|
2012-09-07 |
2018-11-30 |
Regeneron Pharmaceuticals, Inc. |
Sposoby leczenia atopowego zapalenia skóry przez podawanie antagonisty IL-4R
|
|
US20150239970A1
(en)
*
|
2012-10-25 |
2015-08-27 |
Medimmune, Llc |
Stable, Low Viscosity Antibody Formulation
|
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
|
US10111953B2
(en)
|
2013-05-30 |
2018-10-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
|
|
TWI755763B
(zh)
|
2013-06-04 |
2022-02-21 |
美商再生元醫藥公司 |
藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
|
|
TW202021614A
(zh)
|
2013-06-07 |
2020-06-16 |
法商賽諾菲生物技術公司 |
藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法
|
|
AU2014284235C1
(en)
*
|
2013-06-21 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating nasal polyposis by administering an IL-4R antagonist
|
|
TWI634900B
(zh)
|
2013-07-11 |
2018-09-11 |
再生元醫藥公司 |
藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
|
|
US10935554B2
(en)
|
2013-08-23 |
2021-03-02 |
Regeneron Pharmaceuticals, Inc. |
Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT)
|
|
MX2016006226A
(es)
|
2013-11-12 |
2016-09-07 |
Sanofi Biotechnology |
Regimenes de dosificacion para uso con inhibidores de pcsk9.
|
|
IL315136A
(en)
|
2014-02-21 |
2024-10-01 |
Sanofi Biotechnology |
Methods for treating or preventing asthma by administering an il-4rantagonist
|
|
KR102695088B1
(ko)
|
2014-02-28 |
2024-08-16 |
리제너론 파아마슈티컬스, 인크. |
Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법
|
|
PL3169353T3
(pl)
|
2014-07-16 |
2020-06-01 |
Sanofi Biotechnology |
SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH)
|
|
RU2017107847A
(ru)
*
|
2014-09-03 |
2018-10-03 |
Медиммун Лимитед |
Стабильный состав на основе антитела к il-4r-альфа
|
|
CA3246946A1
(en)
|
2014-11-14 |
2025-11-29 |
Sanofi Biotechnology |
Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
|
|
TW202440904A
(zh)
|
2015-08-04 |
2024-10-16 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法（二）
|
|
JP2018523684A
(ja)
|
2015-08-18 |
2018-08-23 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
|
|
ES2983475T3
(es)
|
2016-02-19 |
2024-10-23 |
Regeneron Pharma |
Métodos para mejorar la eficacia de una vacuna mediante la administración de un antagonista de IL-4R
|
|
KR102460040B1
(ko)
|
2016-04-27 |
2022-11-01 |
애브비 인코포레이티드 |
항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
|
|
CN113372446A
(zh)
|
2016-06-08 |
2021-09-10 |
苏州康乃德生物医药有限公司 |
用于结合白细胞介素4受体的抗体
|
|
WO2018039499A1
(en)
|
2016-08-24 |
2018-03-01 |
Regeneron Pharmaceuticals, Inc. |
Host cell protein modification
|
|
ES2994774T3
(en)
|
2016-09-01 |
2025-01-31 |
Regeneron Pharma |
Methods for preventing or treating allergy by administering an il-4r antagonist
|
|
WO2018057776A1
(en)
|
2016-09-22 |
2018-03-29 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
|
|
RU2759630C2
(ru)
|
2016-09-22 |
2021-11-16 |
Ридженерон Фармасьютикалз, Инк. |
Способы лечения тяжелого атопического дерматита путем введения ингибитора il-4r
|
|
US10736961B2
(en)
|
2016-11-29 |
2020-08-11 |
Regeneron Pharmaceuticals, Inc. |
Method of averting opioid addiction
|
|
TWI857389B
(zh)
|
2016-12-01 |
2024-10-01 |
美商再生元醫藥公司 |
治療發炎症狀的方法
|
|
HRP20260303T1
(hr)
|
2016-12-22 |
2026-04-10 |
Regeneron Pharmaceuticals, Inc. |
Postupak za liječenje alergije monoklonskim antitijelima specifičnim za alergen
|
|
KR20200012823A
(ko)
|
2017-02-01 |
2020-02-05 |
예일 유니버시티 |
이뇨제 내성의 치료
|
|
WO2018142514A1
(ja)
*
|
2017-02-01 |
2018-08-09 |
協和発酵キリン株式会社 |
ダルベポエチンを含む液体医薬組成物
|
|
JOP20190260A1
(ar)
*
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
AU2018263868A1
(en)
|
2017-05-02 |
2019-12-12 |
Merck Sharp & Dohme Llc |
Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
|
|
KR102659791B1
(ko)
|
2017-07-06 |
2024-04-23 |
리제너론 파마슈티칼스 인코포레이티드 |
당단백질을 만들기 위한 세포 배양 과정
|
|
US11053309B2
(en)
|
2017-08-04 |
2021-07-06 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating active eosinophilic esophagitis
|
|
KR102694419B1
(ko)
|
2017-10-30 |
2024-08-09 |
사노피 바이오테크놀로지 |
Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
|
|
BR112020010615A2
(pt)
|
2017-12-22 |
2020-10-27 |
Regeneron Pharmaceuticals, Inc. |
produto farmacêutico proteico, método e sistema para caracterizar impurezas de produto farmacêutico proteico e de fármaco de baixo peso molecular, método para produzir um anticorpo, anticorpo, e, usos do método e do sistema
|
|
CA3087699A1
(en)
|
2018-01-05 |
2019-07-11 |
Corvidia Therapeutics, Inc. |
Methods for treating il-6 mediated inflammation without immunosuppression
|
|
CN111655722A
(zh)
|
2018-01-31 |
2020-09-11 |
瑞泽恩制药公司 |
用于表征药物产品杂质的系统和方法
|
|
TW202311746A
(zh)
|
2018-02-02 |
2023-03-16 |
美商再生元醫藥公司 |
用於表徵蛋白質二聚合之系統及方法
|
|
MX2020008988A
(es)
|
2018-02-28 |
2020-09-28 |
Regeneron Pharma |
Sistemas y metodos para la identificacion de contaminantes virales.
|
|
US12253490B2
(en)
|
2018-03-19 |
2025-03-18 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
CA3089655C
(en)
|
2018-03-19 |
2026-01-20 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
US12259355B2
(en)
|
2018-03-19 |
2025-03-25 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
TW202016125A
(zh)
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
|
BR112020020387A2
(pt)
|
2018-05-13 |
2021-01-19 |
Regeneron Pharmaceuticals, Inc. |
Métodos para o tratamento de dermatite atópica por administração de um inibidor de il-4r
|
|
KR20210043624A
(ko)
|
2018-08-10 |
2021-04-21 |
리제너론 파아마슈티컬스, 인크. |
무릎 및/또는 고관절 통증의 안전하고 효과적인 치료를 위한 약제학적 조성물
|
|
MY204234A
(en)
|
2018-08-27 |
2024-08-16 |
Regeneron Pharma |
Use of raman spectroscopy in downstream purification
|
|
AU2019333047A1
(en)
|
2018-08-30 |
2020-12-03 |
Regeneron Pharmaceuticals, Inc. |
Methods for characterizing protein complexes
|
|
KR102885113B1
(ko)
*
|
2018-10-18 |
2025-11-13 |
머크 샤프 앤드 돔 엘엘씨 |
항-rsv 항체의 제제 및 그의 사용 방법
|
|
CN120842406A
(zh)
|
2018-10-31 |
2025-10-28 |
默沙东有限责任公司 |
抗人pd-1抗体晶体及其使用方法
|
|
CN113316458B
(zh)
|
2018-11-07 |
2024-08-02 |
默沙东有限责任公司 |
抗lag3抗体和抗pd-1抗体的共制剂
|
|
KR102330596B1
(ko)
*
|
2018-11-09 |
2021-11-26 |
아주대학교산학협력단 |
인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도
|
|
US11312778B2
(en)
|
2018-11-21 |
2022-04-26 |
Brian C. Machler |
Method for treating allergic contact dermatitis
|
|
ES2942024T3
(es)
|
2019-01-16 |
2023-05-29 |
Regeneron Pharma |
Métodos para caracterizar enlaces disulfuro
|
|
KR102735988B1
(ko)
|
2019-02-18 |
2024-12-03 |
일라이 릴리 앤드 캄파니 |
치료 항체 제제
|
|
MA55204A
(fr)
|
2019-03-06 |
2022-01-12 |
Regeneron Pharma |
Inhibiteurs de la voie il-4/il-13 pour une efficacité améliorée dans le traitement du cancer
|
|
CN111686247B
(zh)
*
|
2019-03-13 |
2022-07-29 |
苏州康乃德生物医药有限公司 |
包含人白介素-4受体α的抗体的液体组合物
|
|
CN113597328B
(zh)
|
2019-03-21 |
2025-10-31 |
瑞泽恩制药公司 |
用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合
|
|
TW202519263A
(zh)
*
|
2019-03-21 |
2025-05-16 |
美商再生元醫藥公司 |
含有抗il-33抗體之穩定調配物
|
|
SG11202111255YA
(en)
|
2019-05-01 |
2021-11-29 |
Sanofi Biotechnology |
Methods for treating or preventing asthma by administering an il-33 antagonist
|
|
EP3969908A1
(en)
|
2019-05-13 |
2022-03-23 |
Regeneron Pharmaceuticals, Inc. |
Improved competitive ligand binding assays
|
|
WO2021011614A1
(en)
|
2019-07-16 |
2021-01-21 |
Sanofi Biotechnology |
Methods for treating or preventing asthma by administering an il-4r antagonist
|
|
JP7836754B2
(ja)
|
2019-08-05 |
2026-03-27 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｉｌ－４ｒアンタゴニストを投与することによりアレルギーを治療しアレルゲン特異的免疫療法を増強するための方法
|
|
CN114173816A
(zh)
|
2019-08-05 |
2022-03-11 |
瑞泽恩制药公司 |
通过施用il-4r拮抗剂治疗特应性皮炎的方法
|
|
EP4653865A3
(en)
|
2019-09-24 |
2026-02-18 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for chromatography use and regeneration
|
|
US12297451B1
(en)
|
2019-10-25 |
2025-05-13 |
Regeneron Pharmaceuticals, Inc. |
Cell culture medium
|
|
WO2021108548A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Sustained release formulations using non-aqueous emulsions
|
|
EP3992974A1
(en)
|
2020-11-02 |
2022-05-04 |
Sanofi Biotechnology |
Methods for treating digitally-identified il-4/il-13 related disorders
|
|
KR20220110829A
(ko)
|
2019-12-09 |
2022-08-09 |
사노피 바이오테크놀로지 |
디지털 식별된 il-4/il-13 관련 장애의 치료 방법
|
|
EP4081544A1
(en)
|
2019-12-23 |
2022-11-02 |
Sanofi Biotechnology |
Methods for treating or preventing allergic asthma by administering an il-33 antagonist and/or an il-4r antagonist
|
|
MX2022008973A
(es)
|
2020-01-21 |
2022-08-11 |
Regeneron Pharma |
Metodos de desglicosilacion para electroforesis de proteinas glicosiladas.
|
|
CA3169959A1
(en)
*
|
2020-02-21 |
2021-08-26 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Pharmaceutical composition containing anti-il-4r antibody and use thereof
|
|
IL296214A
(en)
|
2020-03-27 |
2022-11-01 |
Regeneron Pharma |
Methods for treating atopic dermatitis by administering an il-4r antagonist
|
|
JP2023527775A
(ja)
|
2020-05-22 |
2023-06-30 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｉｌ－４ｒ阻害剤の投与により好酸球性食道炎を処置する方法
|
|
CN113797331A
(zh)
*
|
2020-06-16 |
2021-12-17 |
三生国健药业（上海）股份有限公司 |
一种稳定的抗IL-4Rα单克隆抗体液体制剂
|
|
CN115812080A
(zh)
*
|
2020-07-08 |
2023-03-17 |
瑞泽恩制药公司 |
含有抗ctla-4抗体的稳定调配物
|
|
AU2021332355A1
(en)
|
2020-08-31 |
2023-03-23 |
Regeneron Pharmaceuticals, Inc. |
Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
|
|
US20220169739A1
(en)
|
2020-10-05 |
2022-06-02 |
Sanofi Biotechnology |
Methods for treating asthma in pediatric subjects by administering an il-4r antagonist
|
|
WO2022115588A1
(en)
|
2020-11-25 |
2022-06-02 |
Regeneron Pharmaceuticals, Inc. |
Sustained release formulations using non-aqueous membrane emulsification
|
|
JP2024500409A
(ja)
|
2020-12-17 |
2024-01-09 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
タンパク質封入マイクロゲルの作製
|
|
EP4274609A1
(en)
|
2021-01-08 |
2023-11-15 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
|
|
KR20230134117A
(ko)
|
2021-01-20 |
2023-09-20 |
리제너론 파마슈티칼스 인코포레이티드 |
세포 배양물에서 단백질 역가를 개선시키는 방법
|
|
IL305156A
(en)
|
2021-03-03 |
2023-10-01 |
Regeneron Pharma |
Systems and methods for quantifying and modifying protein viscosity
|
|
AU2022238849A1
(en)
|
2021-03-17 |
2023-08-31 |
Receptos Llc |
Methods of treating atopic dermatitis with anti il-13 antibodies
|
|
BR112023018665A2
(pt)
|
2021-03-26 |
2023-10-03 |
Regeneron Pharma |
Métodos e sistemas para desenvolvimento de protocolos de mistura
|
|
TW202304507A
(zh)
*
|
2021-04-02 |
2023-02-01 |
美商再生元醫藥公司 |
含有抗ｍｕｃ１６ｘ抗ｃｄ３雙特異性抗體之穩定調配物
|
|
EP4348234B1
(en)
|
2021-06-01 |
2026-04-08 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
MX2024001189A
(es)
|
2021-07-26 |
2024-02-27 |
Sanofi Biotechnology |
Metodos para tratar la urticaria cronica espontanea por administracion de un antagonista de il-4r.
|
|
WO2023028468A1
(en)
|
2021-08-23 |
2023-03-02 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating atopic dermatitis by administering an il-4r antagonist
|
|
KR20240053586A
(ko)
*
|
2021-08-26 |
2024-04-24 |
치아타이 티안큉 파마수티컬 그룹 주식회사 |
항il4r 항체의 의약 조성물 및 그의 사용
|
|
US20230077710A1
(en)
|
2021-09-08 |
2023-03-16 |
Regeneron Pharmaceuticals, Inc. |
HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS
|
|
JP2024531800A
(ja)
|
2021-09-20 |
2024-08-29 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗体の不均一性を制御する方法
|
|
CA3230985A1
(en)
|
2021-10-07 |
2023-04-13 |
Ross BROWNE |
Ph meter calibration and correction
|
|
WO2023059800A2
(en)
|
2021-10-07 |
2023-04-13 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods of ph modeling and control
|
|
MX2024004762A
(es)
|
2021-10-20 |
2024-05-08 |
Sanofi Biotechnology |
Metodos para el tratamiento del prurigo nodular mediante la administracion de un antagonista de il-4r.
|
|
CA3236367A1
(en)
|
2021-10-26 |
2023-05-04 |
Michelle Lafond |
Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
|
|
EP4433500A1
(en)
|
2021-11-19 |
2024-09-25 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for reducing centralized pain
|
|
AU2022425608A1
(en)
|
2021-12-30 |
2024-08-15 |
Regeneron Pharmaceuticals, Inc. |
Methods for attenuating atopic march by administering an il-4/il-13 antagonist
|
|
IL315548A
(en)
|
2022-03-18 |
2024-11-01 |
Regeneron Pharma |
Methods and systems for analyzing polypeptide variants
|
|
US20240002491A1
(en)
|
2022-04-27 |
2024-01-04 |
Regeneron Pharmaceuticals, Inc. |
Methods for selecting patients for treatment with an ngf antagonist
|
|
EP4518837A1
(en)
*
|
2022-05-02 |
2025-03-12 |
Regeneron Pharmaceuticals, Inc. |
Anti-interleukin-4 receptor (il-4r) antibody formulations
|
|
WO2024011251A1
(en)
|
2022-07-08 |
2024-01-11 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating eosinophilic esophagitis in pediatric by administering an il-4r antagonist
|
|
JP2025528456A
(ja)
|
2022-08-29 |
2025-08-28 |
サノフィ・バイオテクノロジー |
Ｉｌ－４ｒアンタゴニストの投与による慢性誘発性寒冷蕁麻疹の治療方法
|
|
WO2024097714A1
(en)
|
2022-11-01 |
2024-05-10 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hand and foot dermatitis by administering an il-4r antagonist
|
|
EP4622669A1
(en)
|
2022-11-23 |
2025-10-01 |
Regeneron Pharmaceuticals, Inc. |
Methods for improving bone growth by administering an il-4r antagonist
|
|
EP4634659A1
(en)
|
2022-12-16 |
2025-10-22 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for assessing chromatographic column integrity
|
|
WO2024158961A1
(en)
|
2023-01-25 |
2024-08-02 |
Regeneron Pharmaceuticals, Inc. |
Mass spectrometry-based characterization of antibodies co-expressed in vivo
|
|
US20240245779A1
(en)
|
2023-01-25 |
2024-07-25 |
Regeneron Pharmaceuticals, Inc. |
Methods of modeling liquid protein composition stability
|
|
US20240255519A1
(en)
|
2023-02-01 |
2024-08-01 |
Regeneron Pharmaceuticals, Inc. |
Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
|
|
US20240280551A1
(en)
|
2023-02-22 |
2024-08-22 |
Regeneron Pharmaceuticals, Inc. |
System suitability parameters and column aging
|
|
WO2024197119A1
(en)
|
2023-03-22 |
2024-09-26 |
Sanofi Biotechnology |
Methods for treating chronic obstructive pulmonary disease (copd) by administering an il-4r antagonist
|
|
CN121001741A
(zh)
|
2023-03-27 |
2025-11-21 |
瑞泽恩制药公司 |
用于通过施用il-4r拮抗剂治疗嗜酸粒细胞性胃肠炎的方法
|
|
EP4687971A1
(en)
|
2023-03-30 |
2026-02-11 |
Sandoz Ag |
Stable composition comprising a high protein concentration
|
|
EP4704808A1
(en)
|
2023-05-01 |
2026-03-11 |
Regeneron Pharmaceuticals, Inc. |
Multidose antibody drug products using phenol or benzyl alcohol
|
|
CN119215163A
(zh)
*
|
2023-06-30 |
2024-12-31 |
百奥泰生物制药股份有限公司 |
抗IL-4Rα抗体制剂及其制备方法和应用
|
|
WO2025017034A1
(en)
|
2023-07-17 |
2025-01-23 |
Formycon Ag |
Stable liquid antibody formulation for dupilumab
|
|
TW202528736A
(zh)
|
2023-09-08 |
2025-07-16 |
美商再生元醫藥公司 |
用於評估層析管柱完整性的方法及系統
|
|
WO2025064403A2
(en)
|
2023-09-18 |
2025-03-27 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for developing chromatography protocols
|
|
CN121925272A
(zh)
|
2023-09-29 |
2026-04-24 |
瑞泽恩制药公司 |
利用受控成核进行冻干
|
|
TW202529831A
(zh)
|
2023-10-02 |
2025-08-01 |
美商再生元醫藥公司 |
藥物遞輸裝置安全系統
|
|
WO2025085594A1
(en)
|
2023-10-18 |
2025-04-24 |
Regeneron Pharmaceuticals, Inc. |
Rapid purification of monoclonal antibody from in-process upstream cell culture material
|
|
US20250145662A1
(en)
*
|
2023-11-02 |
2025-05-08 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing lipase activity using stress
|
|
WO2025116648A1
(ko)
*
|
2023-12-01 |
2025-06-05 |
삼성바이오에피스 주식회사 |
항-IL-4Rα 항체의 안정한 완충제-프리 액상 제형
|
|
WO2025116640A1
(ko)
*
|
2023-12-01 |
2025-06-05 |
삼성바이오에피스 주식회사 |
항-IL-4Rα 항체의 안정한 당류-프리 액상 제형
|
|
WO2025116637A1
(ko)
*
|
2023-12-01 |
2025-06-05 |
삼성바이오에피스 주식회사 |
항-IL-4Rα 항체의 안정한 액상 제형
|
|
TW202535949A
(zh)
|
2023-12-20 |
2025-09-16 |
美商必治妥美雅史谷比公司 |
靶向IL-18受體β(IL-18RB)之抗體及相關方法
|
|
WO2025166281A1
(en)
|
2024-02-01 |
2025-08-07 |
Regeneron Pharmaceuticals, Inc. |
Platform for charge-detection mass spectrometry analysis of aavs
|
|
WO2025175164A1
(en)
|
2024-02-16 |
2025-08-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
|
|
TW202602489A
(zh)
|
2024-03-15 |
2026-01-16 |
美商再生元醫藥公司 |
作為經穩定的蛋白質調配物之賦形劑的聚山梨醇酯及聚氧乙烯山梨糖醇酐
|
|
EP4623903A1
(en)
|
2024-03-28 |
2025-10-01 |
Fresenius Kabi Deutschland GmbH |
Pharmaceutical composition comprising dupilumab
|
|
US20250388685A1
(en)
|
2024-04-15 |
2025-12-25 |
Sanofi Biotechnology |
Methods for treating chronic rhinosinusitis without nasal polyps by administering an il-4r antagonist
|
|
CN118105485B
(zh)
*
|
2024-04-26 |
2024-09-03 |
湖南麦济生物技术有限公司 |
一种稳定的抗人IL-4Rα单克隆抗体制剂
|
|
WO2025247342A1
(zh)
*
|
2024-05-30 |
2025-12-04 |
重庆智翔金泰生物制药股份有限公司 |
包含抗il-4r抗体的药物组合物
|
|
WO2025259840A1
(en)
|
2024-06-13 |
2025-12-18 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for scaled chromatography
|
|
WO2025264860A2
(en)
|
2024-06-18 |
2025-12-26 |
Yale University |
Methods of treating post-covid airway disease
|
|
WO2026025028A1
(en)
|
2024-07-26 |
2026-01-29 |
Regeneron Pharmaceuticals, Inc. |
Methods of making ultra-high concentrated protein formulations using lyophilization
|
|
WO2026055687A1
(en)
|
2024-09-09 |
2026-03-12 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating bullous pemphigoid by administering an il-4r antagonist
|
|
WO2026059949A1
(en)
|
2024-09-10 |
2026-03-19 |
Sanofi Biotechnology |
Methods for treating chronic pruritus of unknown origin (cpuo) by administering an il-4r antagonist
|
|
WO2026060350A1
(en)
|
2024-09-13 |
2026-03-19 |
Regeneron Pharmaceuticals, Inc. |
Methods of improving photo stability and controlling formation of hmw species in biologic formulations, and biologic formulations produced by the methods
|
|
WO2026076201A2
(en)
|
2024-10-03 |
2026-04-09 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for producing therapeutic proteins using single pass tangential flow filtration for in-line concentration and volume reduction of production pools
|
|
WO2026080597A1
(en)
|
2024-10-08 |
2026-04-16 |
Regeneron Pharmaceuticals, Inc. |
Sustained delivery of biologics and non-aqueous manufacture of same
|